Blocking programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4), immune checkpoints using antibodies is a highly effective immunotherapeutic strategy for cancer. This evidence concerns the gene CTLA4 and cancer.